Skip to Main Content

Paper Details

Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab.
Drugs Today (Barc)
3
2020
Author NameAffiliation
Maria AmayaUniversity of Colorado School of Medicine
Antonio JimenoUniversity of Colorado School of Medicine
  • 1 - 2

Datasets

Release 1.2